Clinical Trial Update: Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing tiotropium plus olodaterol fixed-dose combination (5/5 µg) versus tiotropium alone (5 µg) to reduce moderate-to-severe COPD e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• olodaterol (olodaterol)
• tiotropium (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2018-06-04